Table 2 |
|||||
|
Random-effects pooled results: duloxetine vs. placebo. |
|||||
|
Outcome |
Treatment effect (θ) |
95% CI for θ |
U-test (p-value) |
τ2 |
NNT/NNH (95% CI) |
|
|
|||||
|
Efficacy |
|||||
|
Reduction in 24-hour pain intensity |
-1.128 |
(-1.364; -0.891) |
<0.001 |
0 |
- |
|
Response |
0.856 |
(0.628; 1.085) |
<0.001 |
0 |
5(3;7) |
|
PGI |
-0.756 |
(-1.004; -0.508) |
<0.001 |
0 |
- |
|
|
|||||
|
Tolerability |
|||||
|
Premature study discontinuation due to: |
|||||
|
- Lack of efficacy |
-0.962 |
(-1.800; -0.124) |
(0.024) |
0 |
|
|
- Adverse events |
1.077 |
(0.663; 1.490) |
<0.001 |
0 |
11 (7; 23) |
|
- Other |
-0.278 |
(-0.636; 0.079) |
(0.127) |
0 |
|
|
Diarrhoea |
0.233 |
(-0.436; 0.903) |
(0.307) |
0.307 |
|
|
Dizziness |
0.817 |
(0.398; 1.235) |
<0.001 |
0 |
|
|
Headache |
0.468 |
(0.090; 0.845) |
(0.015) |
0 |
|
|
Nausea |
1.306 |
(0.942; 1.669) |
0.039 |
0.039 |
|
|
Somnolence |
1.472 |
(1.044; 1.900) |
<0.001 |
0 |
|
|
|
|||||
|
Note: θ is absolute difference for 24-hour pain intensity. θ is log-odds ratio for Response, PGI and all tolerability analyses. τ2 is between-study heterogeneity. NNT/NNH: Number needed to treat, number needed to harm. NNTs were calculated for response rate and NNHs were calculated for discontinuation due to adverse events. |
|||||
|
Quilici et al. BMC Neurology 2009 9:6 doi:10.1186/1471-2377-9-6 |
|||||
